NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON

Vendor Intelligence Report: HK Peptides

Published 12 Nov 2026. 38-page investigative report on who is behind HK Peptides: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

HK Peptides is a product-by-product call, not a brand-level pass. Across 472 Finnrick lab tests, the record is 363 pass / 105 fail, an overall pass rate of 77%. Retatrutide and Tirzepatide sit in the stronger part of the catalog, while CJC-1295 and Tesamorelin define the weak tail. One reported Tirzepatide identity failure, and ratings that contract under stricter grading, keep lot-level verification central.

The corporate trail is more complicated than the Hong Kong-facing storefront suggests. Historical site titles, build paths and sales identities tie the operation to a Zhengzhou company now shown by two Chinese registry indexes as deregistered, while the live HK Peptide Ltd name lacks a matching public HK/UK registration in the sources reviewed. Plausible Hong Kong/Shenzhen manufacturing-side entities are mapped, but no public document ties a current vial to a specific release signatory or lot record.

Authentication is the buyer problem. The report separates the canonical domain from a live hyphenated HK Peptide storefront using copied Advantage text, a ZePeptide-linked “official” lookalike, Worldwide variants, a Vercel demo the vendor labels a scam, and an anti-scam image that conflicts with the site’s own WhatsApp number. Payment evidence is similarly recourse-light, with a documented HK Peptide-name fake-carrier insurance pattern whose attribution remains uncertain.

Inside the full report:

  • Appendix A with per-product pass/fail rates, methodology-divergence charts and trajectories for all 13 products
  • Timeline and corporate-identity trail linking hkpeptide.com, Henan Kuisu, HK Peptide Ltd and registry-index dead ends
  • Lookalike-domain authentication map covering hk-peptides.com, hkpeptides.us, ZePeptide, Worldwide variants, hkpep.cc and the Vercel demo
  • Manufacturing-side analysis of Henan Shengming and YiXiSheng/YXS claims, including the lot-traceability gap
  • Payment, reputation and scam-pattern review covering Reddit, Scamadviser/Gridinsoft and reversible-rail guidance
  • Buyer verification flow for exact domain, contact match, legal seller, lot-matched COA and payment recipient

Risk assessment

  • Corporate-identity and buyer-recourse risk — high: Henan Kuisu, the strongest historical operator, is recorded as deregistered; live HK Peptide Ltd lacks verified HK/UK registration and current UBO.
  • Copycat / brand-confusion risk — high: Multiple live lookalikes or brand hijacks and an official anti-scam phone-number contradiction make channel authentication unsafe without written verification.
  • Product-specific poor-performance risk — high: CJC-1295 (29.34%), TB-500 (44.11%), Sermorelin (44.92%), Tesamorelin (47.79%) and Ipamorelin (55.16%) are weak HK Peptides lines.
  • Tirzepatide lot-identity risk — medium: Tirzepatide is one of HK Peptides’ stronger rows (83.05%), but a 20 mg sample reportedly contained no Tirzepatide; verify the exact lot before use.
  • Payment and post-payment scam exposure risk — medium: Quote-led ordering plus irreversible rails and a documented HK Peptide-name refundable-insurance scam report create practical recourse risk; attribution to the canonical seller is unproven.